Boehringer Ingelheim International GmbH

Boehringer Ingelheim International GmbH

Binger Strasse 173 55216 Ingelheim am Rhein

Depression

Depression

Depression

2020 was a year of uncertainty, driven by the global pandemic and its enforced isolation and loss of personal connections to loved ones. The world has unfortunately also seen a steady rise in the number of people experiencing some form of depression. Over two-thirds of people who have experienced mental health problems prior to the pandemic have said their mental health has worsened during lockdown, with symptoms resurfacing with renewed frequency and intensity.1 A recent US study also identified that COVID-19 virus infection may have a direct link to increased risk of mental illness.2 This may even be the case for people who have never had a mental illness diagnosis.

So where does that leave us? On the one hand, the increasing attention on mental health as a result of the pandemic can go a long way towards addressing existing stigma. However, we also know that many people living with depression have no adequate treatment options; up to a third of people living with depression do not respond to current treatments.3

Now more than ever, we need to think about how we can work more closely with those living with mental illnesses, such as depression, to pioneer new solutions. We need to reverse the status quo and find new – and creative – ways to help. To date, participation in hospital-based clinical trials has been the norm for the rigorous development process of new treatments. Now, the use of digital technology has the potential to be a game changer by enabling decentralized clinical trials (DCTs) to overcome geographic and other barriers.

What is a decentralized clinical trial (DCT)?

There are multiple types of DCTs. For example, participants can engage in outcome assessments with a mobile nurse from the privacy of their homes. A DCT can also incorporate multiple digital health technologies (e.g. telemedicine, mobile apps, smartphone) which can reduce some of the burdens associated with traditional research. This expands the access and opportunity of participation to a broader portion of patients with depression.

Product Enquiry

SSL Secure Connection